Business, energy, technology, markets and global industry news from Business News Today

Keymed Biosciences

PharmaDeviceNews Keymed Biosciences
Belenos Biosciences’ BEL512 has delivered positive Phase 2 results in chronic rhinosinusitis with nasal polyps, supporting further development of the long-acting bispecific antibody as the company prepares for Phase 3 testing. Representative image.
Pharma & Biotech

What do BEL512 Phase 2 results mean for Belenos Biosciences and CRSwNP treatment?

Belenos says BEL512 met all Phase 2 CRSwNP endpoints, but undisclosed effect sizes make the planned 2027 Phase 3 trial the critical test.

Read More
AstraZeneca’s investigational CLDN18.2 antibody-drug conjugate sonesitatug vedotin improved overall survival in a Phase 3 trial involving previously treated advanced gastric and gastroesophageal junction cancers, although the progression-free survival endpoint was not statistically significant. Representative image.
Pharma & Biotech

Sonesitatug vedotin Phase 3 survival win strengthens AstraZeneca’s gastric cancer ADC strategy

Read why AstraZeneca’s sonesitatug vedotin survival win in CLDN18.2-positive gastric cancer is tempered by a Phase 3 PFS miss.

Read More
Pharma & Biotech

Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition

Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.

Read More